Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. 2003

Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
Erasmus MC/University Medical Center Rotterdam/Sophia Children's Hospital, Division of Pediatric Oncology/Hematology, Rotterdam, The Netherlands. stams@kgk.fgg.eur.nl

The (12;21) translocation resulting in TEL/AML1 gene fusion is present in about 25% of childhood precursor B-lineage acute lymphoblastic leukemia (ALL) and is associated with a good prognosis and a high cellular sensitivity to L-asparaginase (L-Asp). ALL cells are thought to be sensitive to L-Asp due to lower asparagine synthetase (AS) levels. Resistance to L-Asp may be caused by an elevated cellular level of AS or by the ability of resistant cells to rapidly induce the expression of the AS gene on L-Asp exposure. AS may be a target regulated by t(12;21). We studied the relationship between t(12;21) and the mRNA level of AS to investigate a possible mechanism underlying L-Asp sensitivity. Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis surprisingly revealed that 30 patients positive for t(12;21) expressed 5-fold more AS mRNA compared with 17 patients negative for t(12;21) (P =.008) and 11 samples from healthy controls (P =.016). The mRNA levels of AS between t(12;21)(-) ALL and healthy controls did not differ. No difference was found between ALL patients positive or negative for t(12;21) in the capacity to up-regulate AS after in vitro L-Asp exposure, excluding a defective capacity for t(12;21) cells in up-regulating AS on L-Asp exposure. Moreover, no correlation was observed between AS mRNA expression and sensitivity to L-Asp. We conclude that the sensitivity of t(12;21)(+) childhood ALL to L-Asp is not associated with the expression level of the AS gene. Furthermore, we contradict the general thought that leukemic cells specifically lack AS compared with normal bone marrow and blood cells.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002881 Chromosomes, Human, Pair 12 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 12
D002891 Chromosomes, Human, Pair 21 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 21
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001215 Asparaginase A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. Asparaginase II,Asparaginase medac,Asparagine Deaminase,Colaspase,Crasnitin,Elspar,Erwinase,Kidrolase,Leunase,Paronal,Deaminase, Asparagine,medac, Asparaginase
D001217 Aspartate-Ammonia Ligase An enzyme that catalyzes the formation of asparagine from ammonia and aspartic acid, in the presence of ATP. EC 6.3.1.1. Asparagine Synthase,Asparagine Synthetase,Asparagine Synthetase B,Aspartate Ammonia Ligase,Ligase, Aspartate-Ammonia,Synthase, Asparagine,Synthetase B, Asparagine,Synthetase, Asparagine
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic

Related Publications

Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
June 2006, Blood,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
January 2018, OncoTargets and therapy,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
August 2012, Experimental hematology,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
December 2006, Leukemia,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
June 2010, Zhongguo shi yan xue ye xue za zhi,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
October 1969, Biochemical pharmacology,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
July 2001, The Biochemical journal,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
September 1968, Archives of biochemistry and biophysics,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
May 1991, Biochemistry international,
Wendy A G Stams, and Monique L den Boer, and H Berna Beverloo, and Jules P P Meijerink, and Rolinda L Stigter, and Elisabeth R van Wering, and Gritta E Janka-Schaub, and Rosalyn Slater, and Rob Pieters
June 2014, Leukemia & lymphoma,
Copied contents to your clipboard!